The board of directors of Aceso Life Science Group Limited announced that, based on the preliminary assessment of the Group's unaudited consolidated management accounts for the six months ended 30 September 2022 and all the information currently available to the Board, the Group is expected to record Loss for the Period at approximately of HKD 4 million as compared to Loss for the Period at approximately HKD 130 million for the six months ended 30 September 2021.